This paediatric-focused study evaluates annual changes in the incidence and prevalence rates of respiratory pathogens across different age groups, while also comparing medication prescription trends over an 18-year period. This study provides valuable data from a real-world clinical setting where infants under the age of one receive universal antimicrobial prophylaxis and, standardised respiratory pathogen surveillance is conducted by qualified personals using consistent sampling and microbiological testing protocols. In particular, obtaining samples through sputum and oropharyngeal suctioning is considered to have the highest concordance with BAL samples, rendering them more representative of lower airway infections compared to other sampling methods like throat or cough swabs18. The findings contribute to our understanding of the long-term trends in respiratory pathogens and associated clinical management in the paediatric population, particularly in the modern era of eradication therapy15.
Our study showed that together, S. aureus and P. aeruginosa make up the majority of respiratory pathogens both in terms of incidence (51.3%) and prevalence (82.3%). Data preceding 2000, report prevalence of these two respiratory pathogens to be higher at 95%14.
Registry data taken from 2018 to 2020 showed a prevalence of P. aeruginosa of 20.9%17 and S. aureus of 55.26% in children and adolescents under the age of 18. In comparison, our data shows a recent prevalence of P. aeruginosa of 17.6% and S. aureus of 45.3%. Of the less frequent respiratory pathogens, NTM prevalence was 4.3% from registry data vs 3.7% from our cohort and B.cepaciawas 3.2% vs. 1.3% respectively.
In a recent publication by VanDevanter et al., a trend of decline in P. aeruginosa prevalence was observed, as evidenced by the examination and presentation of registry data within a comparable time frame19. Following this, Fischer et al. raised a crucial question regarding whether the observed changes in P. aeruginosa over time were also apparent in other respiratory pathogens of interest in CF20. We have demonstrated that over the past 18years, the incidence and prevalence of the most common respiratory pathogens in CF such as S. aureus, P. aeruginosa, H. influenzae and A. fumigatus have decreased steadily. This significant decline of between 2 and 4% of individual respiratory pathogens are observed both in the incidence and prevalence. Meanwhile, less common organisms such as NTM, B. cepacia and A. xylosoxidans, S. maltophilia showed no significant change in terms of incidence and prevalence.
We also found that the incidence and prevalence of respiratory pathogens remain unchanged for infants up to 2years of age across all respiratory pathogens. Additionally, we have found that our cohort of children and adolescents with CF are found to have a positive airway sample culture for these respiratory pathogens significantly later that the earlier years of this study.
Our centre has adopted the universal use of S. aureus prophylactic antibiotics in infants diagnosed with CF preceding this study period. In a systematic analysis performed which reviewed four studies, there was a weak indication that P.aeruginosa was isolated less frequently in children under three years and more frequently in children between three to six years in the prophylactic group21. In contrast, despite our universal use of prophylactic antibiotics in infants, our study shows (1) a decline in the incidence and prevalence of P. aeruginosa, (2) no significantincrease in the incidence and prevalence of organisms such as NTM and B. cepacia (3) an increase in the mean age of first isolation of respiratory pathogens of interest, (4) no change of incidence and prevalence of respiratory pathogen<2years of age. A contributing factor in terms of improvements in infection control practices may have helped keep our incidence and prevalence lower than the national average. While being potentially circumstantial, these findings suggest that the use of prophylactic anti-staphylococcal antibiotics is not associated with an increase in P. aeruginosa or increase in prevalence of other less common respiratory pathogen. Prospective studies such as the CF-START study in evaluating outcomes of prophylactic treatments will hopefully provide conclusive proof of its benefits and safety21.
By examining prescription trends, we have found that there is a rise in the use of anti-pseudomonal nebulised antibiotics such as amikacin and colistin. This suggests that P.aeruginosa is being more aggressively treated over time as both this antibiotics are considered as second line after tobramycin22. However, the increase in use of amikacin could also be attributed to an increase in NTM incidence and prevalence. Encouragingly, we have found that the emphasis on respiratory clearance has increased over time with the significant increase in the prescription of dornase alpha and hypertonic saline in our cohort.
Our study comes with certain limitations that warrant consideration. Firstly, the sputum and prescription data lack representation from external laboratories or pharmacies, potentially limiting the comprehensiveness of our findings. Additionally, we did not culture anaerobic bacteria and did not routinely test for co-infection with respiratory viruses, leading to an omission in addressing potential co-infections among these organisms in our study. Moreover, the annual frequency of NTM testing, as opposed to routine CF airway sample cultures, may result in an underrepresentation of NTM within our study cohort.
Thirdly, our data originated from a single CF centre in Australia, raising concerns about the generalisability of our findings to a broader population. Fourthly, our incidence calculation may involve a small number of children or adolescents intermittently found to have these respiratory pathogens in their airway samples. Finally, the relatively limited sample size of children and adolescents on CFTR modulators or correctors is noteworthy, as our study predates the widespread adoption that followed the approval and government funding of these medications in Australia. Current evidence suggests that while it may more difficult to obtain sputum samples in children on CFTR therapy, its impact on the growth of specific bacterial pathogens needs to be closely examined23. The low number of children or adolescents on CFTR modulators or correctors is an important aspect of this study as it will enable future comparison in a post-modulator era in the management of CF.
Our study has several strengths. First, we analysed a large number of sputum samples, both overall and in different age groups, providing a longitudinal comparison of changes in CF treatment over the past 18years. This is the first study of such magnitude in children and adolescents with CF, providing age-specific incidence and prevalence, as well as prescription trends. In particular, our review of incidences of these organisms and the age of first positive culture provides additional information towards our understanding of CF respiratory pathogens over the past two decades.
Second, our study includes a large cohort of children born on or after January 1st, 2002, when newborn screening has already been well-established, allowing us to assess the acquisition of respiratory pathogens from shortly after birth over the past 18years. Third, the practice of using prophylactic anti-staphylococcus antibiotics universally has given us the opportunity to assess the outcomes of its use over a significantly long period of time. While strong conclusions cannot be made without a non-prophylactic control arm, it does provide insight into the long-term impact of its implementation on respiratory pathogens in our cohort.
In summary, our study shows a change in the epidemiology of CF pathogens in a single large paediatric clinic that practices universal prophylaxis in children. First, we observed a decline in the incidence and prevalence of the most commonly found CF pathogens such as S. aureus, P. aeruginosa, H. influenzae, and A. fumigatus, as well as a delay in the first acquisition of these pathogens. However, less common pathogens such as S. marcescens, NTM, B. cepacia, A. xylosoxidans, and S. maltophilia did not show significant changes. Second, we found no change in the incidence or prevalence of respiratory pathogens in infants under 2years of age over time.
Read the rest here:
- Lowe's Teams Up with Lionel Messi, Inter Miami CF and CONMEBOL Copa Amrica 2024 USA to Win Over Soccer ... - Lowes Corporate - April 20th, 2024 [April 20th, 2024]
- Canyon Endurace CF SLX 8 AXS Aero All in the name of speed and distance? - GRAN FONDO Cycling Magazine - April 20th, 2024 [April 20th, 2024]
- Porosome treatment targeting CFTR shows promise in CF models - Cystic Fibrosis News Today - April 20th, 2024 [April 20th, 2024]
- The Reign of Girls Generation's YoonA in Endorsements: The CF Queen - allkpop - April 20th, 2024 [April 20th, 2024]
- Lowe's Teams Up with Lionel Messi, Inter Miami CF and CONMEBOL Copa Amrica 2024 USA to Win Over Ftbol ... - Inter Miami CF - April 20th, 2024 [April 20th, 2024]
- Controlling anxiety is a key part of managing my health with CF - Cystic Fibrosis News Today - April 20th, 2024 [April 20th, 2024]
- Orlando City at CF Montreal: Three Keys to Victory - The Mane Land - April 20th, 2024 [April 20th, 2024]
- Learn to Evaluate (CF) using the Charts - Stock Traders Daily - April 20th, 2024 [April 20th, 2024]
- CF Industries and JERA Announce Joint Development Agreement to Develop Greenfield Low-Carbon Ammonia ... - Business Wire - April 20th, 2024 [April 20th, 2024]
- CF Montreal plays Orlando City in conference action - FOX Sports - April 20th, 2024 [April 20th, 2024]
- CF Montral: What is the ceiling for Josef Martnez's new team? | MLSSoccer.com - MLSsoccer.com - April 20th, 2024 [April 20th, 2024]
- Spotlight on CF Industries Holdings: Analyzing the Surge in Options Activity - CF Industries Holdings (NY - Benzinga - April 20th, 2024 [April 20th, 2024]
- Mamardashvili boast the highest spot-kick saves this season - Valencia CF - April 20th, 2024 [April 20th, 2024]
- Jaume Domnech: "I have the VCF DNA inside me" - Valencia CF - April 20th, 2024 [April 20th, 2024]
- MATCH RECAP: Inter Miami CF Earns 2-3 Win on the Road Over Sporting Kansas City at a Packed Arrowhead Stadium - Inter Miami CF - April 20th, 2024 [April 20th, 2024]
- Pavel "The Experiment" Dailidko: Undefeated in 2023 and Charging into BRAVE CF 81 this Saturday, April 20 - Black Belt Magazine - April 20th, 2024 [April 20th, 2024]
- JERA and CF Industries Holdings sing ammonia production deal - SAFETY4SEA - April 20th, 2024 [April 20th, 2024]
- Lowe's Teams Up with Lionel Messi, Inter Miami CF and CONMEBOL Copa Amrica 2024 USA to Win Over Soccer ... - PR Newswire - April 20th, 2024 [April 20th, 2024]
- CF Industries Holdings, Inc. (NYSE:CF) Shares Purchased by Mirae Asset Global Investments Co. Ltd. - Defense World - April 20th, 2024 [April 20th, 2024]
- CF: Milan to jump above Juventus in UEFA ranking for first time in 10 years - Sempre Milan - April 20th, 2024 [April 20th, 2024]
- Color Star's Partner Team Villarreal CF Bests Real Madrid CF Once Again As The Yellow Submarine Maintains Its Impressive Win Record -... - April 19th, 2023 [April 19th, 2023]
- Brave CF 70 Slovenia: Joilton Lutterbach vs. Andreas Gustafsson; Date, fight times, how to watch on DAZN - dazn.com - April 19th, 2023 [April 19th, 2023]
- Malaga CF owner Sheikh Al-Thani vows never to put the club he has run into the ground up for sale - The Olive Press - April 19th, 2023 [April 19th, 2023]
- CF Industries partnering with South Korea firm on $2 billion blue ammonia project in Ascension - The Advocate - March 4th, 2023 [March 4th, 2023]
- Cystic Fibrosis (CF): Causes, Symptoms, Diagnosis & Treatment - February 7th, 2023 [February 7th, 2023]
- Reg CF: 2022 Delivered A Decline For Investment Crowdfunding As Economy Slowed, But Expectations Going - Crowdfund Insider - February 7th, 2023 [February 7th, 2023]
- Cystic fibrosis life expectancy: Averages by stage and age - February 2nd, 2023 [February 2nd, 2023]
- Cystic Fibrosis Carrier: What You Should Know - Healthline - February 2nd, 2023 [February 2nd, 2023]
- Cystic Fibrosis: Prenatal Screening and Diagnosis | ACOG - February 2nd, 2023 [February 2nd, 2023]
- CF Moto to launch a retro mini bike, will compete with Honda Grom in the international markets, all we know so far - DNP INDIA - February 2nd, 2023 [February 2nd, 2023]
- CF Industries Holdings, Inc. (NYSE:CF) Short Interest Down 10.3% in October - MarketBeat - November 16th, 2022 [November 16th, 2022]
- Will CF Industries Holdings, Inc. (CF) Stay at the Top of the Basic Materials Sector? - InvestorsObserver - October 25th, 2022 [October 25th, 2022]
- Wanyama on Sunday played his last match for CF Montreal- Here are potential destinations - The Standard - October 25th, 2022 [October 25th, 2022]
- Scouting Report: 5 things you should know about CF Montral when they play NYCFC in the MLS Cup Playoffs - Hudson River Blue - October 21st, 2022 [October 21st, 2022]
- 2-year-old living with cystic fibrosis helped by new treatments - 11Alive.com WXIA - October 13th, 2022 [October 13th, 2022]
- Phage Trial to Treat CF Patients with Multi-Drug Resistant Bacterial Infections - UC San Diego Health - October 13th, 2022 [October 13th, 2022]
- High Blood-sugar Levels at Night Affect Lung Function in CF Adults... - Cystic Fibrosis News Today - October 13th, 2022 [October 13th, 2022]
- This 7-year-old is finally on a 'life-changing' cystic fibrosis drug. For others in Ontario, access is tricky - CBC.ca - October 13th, 2022 [October 13th, 2022]
- CF's Thomas and Easttam dodge Panthers' high-powered defense, tackle running offense head-on - Camden News - October 13th, 2022 [October 13th, 2022]
- The Difficulties of Diving Back In After Taking a Hiatus | Cystic... - Cystic Fibrosis News Today - October 13th, 2022 [October 13th, 2022]
- Cystic Fibrosis Market to Showcase Growth at a CAGR of 9% During the Forecast Period (2022-2032) | DelveInsight - PR Newswire - October 13th, 2022 [October 13th, 2022]
- Massive Predictions: Columbus Crew at CF Montral - Massive Report - September 9th, 2022 [September 9th, 2022]
- Why CF Acquisition Corp. VI Blasted 14% Higher Today - The Motley Fool - September 9th, 2022 [September 9th, 2022]
- Watch Real Betis vs. Villarreal CF Online: Live Stream, Start Time - For The Win - September 9th, 2022 [September 9th, 2022]
- Watch Getafe CF vs. Real Sociedad Online: Live Stream, Start Time - For The Win - September 9th, 2022 [September 9th, 2022]
- Mauro Icardi linked with move to Inter Miami CF - AS USA - September 9th, 2022 [September 9th, 2022]
- CF Acquisition (NASDAQ:CFVI) Rumble Takes On Traditional Media Outlets With New 'Rumble Exclusives' Liv - Benzinga - September 9th, 2022 [September 9th, 2022]
- SF Giants CF struggles on triple by Klay's brother - SFGATE - July 25th, 2022 [July 25th, 2022]
- CF Industries Holdings, Inc. Statement Regarding ITC Injury Determination Concerning Imports of UAN from Russia and Trinidad and Tobago - Business... - July 25th, 2022 [July 25th, 2022]
- CF man jailed in hit-and-run case - Leader-Telegram - July 25th, 2022 [July 25th, 2022]
- AEG and Socios.com Launch Partnership for the Inaugural Soccer Champions Tour Featuring Real Madrid CF, FC Barcelona, Juventus, Club America and Club... - July 25th, 2022 [July 25th, 2022]
- Taty Castellanos plays his final game for NYCFC in 2-0 home win - Hudson River Blue - July 25th, 2022 [July 25th, 2022]
- Padres' Fernando Tatis Jr.: Position Change to CF from SS 'Not out of the Question' - Bleacher Report - July 25th, 2022 [July 25th, 2022]
- CF Industries Stock: From Boom To Bust - Sell Into The Rallies (NYSE:CF) - Seeking Alpha - June 20th, 2022 [June 20th, 2022]
- CF graduates to chart their own paths to success - Valley Breeze - June 20th, 2022 [June 20th, 2022]
- Poirier: We need the strength of the fans" - Real Madrid CF - June 20th, 2022 [June 20th, 2022]
- Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis... - June 11th, 2022 [June 11th, 2022]
- Jayda Coleman, Oklahoma CF, robs Texas of a home run at the wall - Saturday Down South - June 11th, 2022 [June 11th, 2022]
- Gennaro Gattuso brings tenacity and technique to the Valencia CF dugout - Yardbarker - June 11th, 2022 [June 11th, 2022]
- 77-85: On to the league final - Real Madrid CF - June 11th, 2022 [June 11th, 2022]
- Gator Greats On CF Hall of Fame Ballot - ESPN 98.1 FM - 850 AM WRUF - WRUF - June 11th, 2022 [June 11th, 2022]
- Mariners CF Julio Rodrguez named AL Rookie of the Month for May - Seattle Sports - June 5th, 2022 [June 5th, 2022]
- CF woman charged with theft of trade secrets from former employer - Leader-Telegram - June 5th, 2022 [June 5th, 2022]
- Laso: The team were magnificent in defense" - Real Madrid CF - June 5th, 2022 [June 5th, 2022]
- The Austrian Wonderboy Returns To Action At BRAVE CF 59 in Uzbekistan - FightBook MMA - June 5th, 2022 [June 5th, 2022]
- Son Ye Jin Teases Fans With First CF Since Wedding to Hyun Bin - Kdramastars - June 5th, 2022 [June 5th, 2022]
- Fourth anniversary of the Duodcima - Real Madrid CF - June 5th, 2022 [June 5th, 2022]
- Meet the Avro CF-105 Arrow: The Long-Ranger Fighter Designed to Battle Russia - 19FortyFive - June 5th, 2022 [June 5th, 2022]
- Charlottetown to host professional soccer match between Sunderland AFC, CF Montral U23 teams - Saltwire - June 5th, 2022 [June 5th, 2022]
- Neutrophil Dysfunction in the Pathogenesis of Cystic Fibrosis (CF) - Physician's Weekly - May 21st, 2022 [May 21st, 2022]
- CF Industries Holdings, Inc. (NYSE:CF) Expected to Announce Earnings of $6.16 Per Share - Defense World - May 21st, 2022 [May 21st, 2022]
- Living with Cystic Fibrosis: A CF patient experience story | LHSC - London Health Sciences Centre - May 21st, 2022 [May 21st, 2022]
- CF Montreals Ismal Kon is showing impressive promise early this MLS season - The Athletic - May 21st, 2022 [May 21st, 2022]
- Film produced by CF native to be shown at Micon Cinemas - Leader-Telegram - May 21st, 2022 [May 21st, 2022]
- CF & CFRP Market Research Report by Carbon Fiber Materials, Resin Type, Manufacturing Process, End-use Industry, Region - Global Forecast to 2027... - May 21st, 2022 [May 21st, 2022]
- Experienced defensive backs for CF thriving this off-season - Camden News - May 21st, 2022 [May 21st, 2022]
- The 37th anniversary of Real Madrid's first UEFA Cup - Real Madrid CF - May 21st, 2022 [May 21st, 2022]
- Q&A: How a Cystic fibrosis diagnosis has changed in recent years - WRAL News - May 6th, 2022 [May 6th, 2022]
- Kinnear: Hope, Turning CF Into 'Cure Found' and Betting on the Long Shot - insidelacrosse.com - May 6th, 2022 [May 6th, 2022]
- CF INDUSTRIES HOLDINGS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q) - Marketscreener.com - May 6th, 2022 [May 6th, 2022]